Trial abstract · §3
GETGOAL-DUO-1 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in glycated haemoglobin from baseline to week 24 after insulin glargine titration | Additional glycaemic effect concentrated in the postprandial period | High |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Lixisenatide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 25.0 | 7.0 | GetGoal pooled |
| Vomiting | 10.0 | 2.0 | GetGoal pooled |
| Headache | 8.0 | 6.0 | GetGoal pooled |
| Symptomatic hypoglycaemia (with sulfonylurea) | 22.0 | 13.0 | GetGoal pooled |
| Antibody formation | 70.0 | — | GetGoal pooled — high incidence; efficacy attenuated only at very high titre |
| Discontinuation for adverse events | 7.0 | 3.0 | GetGoal pooled |
Compound Evidence Institute · CEI-TR-0091/3 · https://compoundevidence.com/trials/getgoal-duo-1/results/ · retrieved 30 July 2026